Francois Gueyffier

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. pmc Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review
    Rémy Boussageon
    UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, CNRS, Universite Claude Bernard Lyon 1, Villeurbanne F 69100, France
    BMC Med Res Methodol 13:107. 2013
  2. pmc Individual patient data meta-analysis of survival data using Poisson regression models
    Michael J Crowther
    Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Adrian Building, University Road, Leicester LE1 7RH, UK
    BMC Med Res Methodol 12:34. 2012
  3. pmc Standard requirements for GCP-compliant data management in multinational clinical trials
    Christian Ohmann
    Coordination Centre for Clinical Trials, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
    Trials 12:85. 2011
  4. pmc Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres
    Wolfgang Kuchinke
    Coordination Centre for Clinical Trials, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
    Trials 11:79. 2010
  5. pmc Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients
    Caroline Guignant
    Hospices Civils de Lyon, Hôpital E, Herriot, Laboratoire d Immunologie, 5 Place d Arsonval, 69003 Lyon, France
    Crit Care 15:R99. 2011
  6. ncbi request reprint [What is the place for intermediate outcomes one cardiovascular prevention is achieved?]
    Francois Gueyffier
    centre d investigation clinique, Hopital Louis Pradel, Lyon, France
    Therapie 58:31-6. 2003
  7. ncbi request reprint [Causality and statistical association (2) Mechanical determinism and stochastic model]
    Francois Gueyffier
    Service de pharmacologie clinique Faculté RTH Laennec 69008 Lyon
    Rev Prat 53:933-6. 2003
  8. ncbi request reprint [Statistical cause and association (I). Critique of the cause]
    Francois Gueyffier
    Centre d investigation clinique Hôpital cardiovasculaire et pneumologique Louis Pradel 69500 Bron
    Rev Prat 53:817-9. 2003
  9. ncbi request reprint [Cardiovascular prevention and large clinical trials]
    Francois Gueyffier
    Service de pharmacologie clinique EA 3736, centre d investigation clinique CIC de Lyon, Hopital Louis Pradel, 69677 Bron
    Rev Prat 55:1774-82. 2005
  10. ncbi request reprint [Critical reading of articles: an essential aspect of modern medical training]
    Francois Gueyffier
    Service de Pharmacologie Clinique, Hopital Cardiovasculaire et Pneumologique Louis Pradel, 69677 Bron Lyon Cedex, France
    Rev Prat 59:20-4. 2009

Collaborators

Detail Information

Publications41

  1. pmc Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review
    Rémy Boussageon
    UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, CNRS, Universite Claude Bernard Lyon 1, Villeurbanne F 69100, France
    BMC Med Res Methodol 13:107. 2013
    ..We wanted to determine if these concomitant treatments were correctly reported in articles of RCTs on type 2 diabetes and if they might have influenced the outcome...
  2. pmc Individual patient data meta-analysis of survival data using Poisson regression models
    Michael J Crowther
    Centre for Biostatistics and Genetic Epidemiology, Department of Health Sciences, University of Leicester, Adrian Building, University Road, Leicester LE1 7RH, UK
    BMC Med Res Methodol 12:34. 2012
    ..We describe an alternative approach using Poisson based Generalised Linear Models (GLMs)...
  3. pmc Standard requirements for GCP-compliant data management in multinational clinical trials
    Christian Ohmann
    Coordination Centre for Clinical Trials, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
    Trials 12:85. 2011
    ....
  4. pmc Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres
    Wolfgang Kuchinke
    Coordination Centre for Clinical Trials, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
    Trials 11:79. 2010
    ....
  5. pmc Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients
    Caroline Guignant
    Hospices Civils de Lyon, Hôpital E, Herriot, Laboratoire d Immunologie, 5 Place d Arsonval, 69003 Lyon, France
    Crit Care 15:R99. 2011
    ..It has recently been shown that PD-1 knock-out mice exhibited a lower mortality in response to experimental sepsis. The objective of the present study was to investigate PD-1-related molecule expressions in septic shock patients...
  6. ncbi request reprint [What is the place for intermediate outcomes one cardiovascular prevention is achieved?]
    Francois Gueyffier
    centre d investigation clinique, Hopital Louis Pradel, Lyon, France
    Therapie 58:31-6. 2003
    ....
  7. ncbi request reprint [Causality and statistical association (2) Mechanical determinism and stochastic model]
    Francois Gueyffier
    Service de pharmacologie clinique Faculté RTH Laennec 69008 Lyon
    Rev Prat 53:933-6. 2003
  8. ncbi request reprint [Statistical cause and association (I). Critique of the cause]
    Francois Gueyffier
    Centre d investigation clinique Hôpital cardiovasculaire et pneumologique Louis Pradel 69500 Bron
    Rev Prat 53:817-9. 2003
  9. ncbi request reprint [Cardiovascular prevention and large clinical trials]
    Francois Gueyffier
    Service de pharmacologie clinique EA 3736, centre d investigation clinique CIC de Lyon, Hopital Louis Pradel, 69677 Bron
    Rev Prat 55:1774-82. 2005
    ..Practitioners must be trained to use these new concepts and tools...
  10. ncbi request reprint [Critical reading of articles: an essential aspect of modern medical training]
    Francois Gueyffier
    Service de Pharmacologie Clinique, Hopital Cardiovasculaire et Pneumologique Louis Pradel, 69677 Bron Lyon Cedex, France
    Rev Prat 59:20-4. 2009
    ..A few key elements are provided to the students following this career...
  11. pmc Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    BMJ 343:d4169. 2011
    ..To determine all cause mortality and deaths from cardiovascular events related to intensive glucose lowering treatment in people with type 2 diabetes...
  12. pmc Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
    Rémy Boussageon
    Department of General Medicine, Universite Claude Bernard Lyon 1, Lyon, France
    PLoS Med 9:e1001204. 2012
    ..Since then, it has been the first-line treatment in overweight patients with type 2 diabetes. However, metformin-sulphonylurea bitherapy may increase mortality...
  13. ncbi request reprint Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments
    Jean Pierre Boissel
    Service de Pharmacologie Clinique, Claude Bernard University, Faculté RTH Laennec, Rue G Paradin, 69376 Lyon, France
    Fundam Clin Pharmacol 19:579-84. 2005
    ..This result suggests that the apparent effect on blood pressure is not the only cause of stroke risk reduction in hypertensive subjects submitted to an antihypertensive medicine...
  14. pmc Treatment of high blood pressure and gain in event-free life expectancy
    Behrouz Kassai
    Department of Clinical Pharmacology, Claude Bernard University, Lyon, France
    Vasc Health Risk Manag 1:163-9. 2005
    ..Consideration of absolute risk has been recommended for making decisions concerning preventive treatment in hypertension. We performed simulations to estimate the benefit of antihypertensive therapy over a life-time...
  15. doi request reprint Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials
    Theodora Bejan-Angoulvant
    Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France
    J Hypertens 28:1366-72. 2010
    ..However, inconsistencies exist with regard to the effect of these drugs on total mortality...
  16. doi request reprint SCORE should be preferred to Framingham to predict cardiovascular death in French population
    Ivanny Marchant
    IMTh Institute for Theoretical Medicine CNRS, UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, Service de Pharmacologie Clinique, Lyon, France
    Eur J Cardiovasc Prev Rehabil 16:609-15. 2009
    ..Numerous studies have examined the validity of available scores to predict the absolute cardiovascular risk...
  17. ncbi request reprint Pharmacogenetics and responders to a therapy: theoretical background and practical problems
    Jean Pierre Boissel
    Clinical Pharmacology Department, Academic Hospital, Lyon, France
    Clin Chem Lab Med 41:564-72. 2003
    ..No method is currently both fully adequate and validated. Finally, the predictive models, which we need to identify responders, do not exist in practice. Fortunately, new research approaches have been developed recently...
  18. doi request reprint [Critical of the additive model of the randomized controlled trial]
    Rémy Boussageon
    Département de médecine générale, Lyon, France
    Therapie 63:29-35. 2008
    ....
  19. ncbi request reprint The IDEAL study : towards personalized drug treatment of hypertension
    Theodora Bejan-Angoulvant
    Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France UMR 5558, CNRS, Villeurbanne, France Claude Bernard Lyon 1 University, Lyon, France
    Therapie 67:195-204. 2012
    ..To identify markers (phenotypic, genetic, or environmental) of blood pressure (BP) response profiles to angiotensin converting enzyme inhibitors (ACEIs) and diuretics...
  20. ncbi request reprint Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II
    Florent Boutitie
    Hospices Civils de Lyon, Service de Biostatistique, Lyon, université de Lyon I, Villeurbanne, CNRS, UMR 5558, Laboratoire Biostatistique Santé, Pierre Benite, France
    J Hypertens 25:1543-53. 2007
    ..The present meta-analysis of various randomized clinical trials attempts to relate stroke risk to angiotensin II formation during antihypertensive therapy...
  21. ncbi request reprint [Preventing dependency in elderly persons: randomized study in the community]
    Catherine Cornu
    CIC de Lyon, Hopital Cardiologique, Bron, France
    Therapie 58:451-6. 2003
    ..This network, comprising stable workers (14 years of work experience on average in this study) offers the potential for future research in the community to evaluate preventive measures...
  22. ncbi request reprint Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock
    Guillaume Monneret
    Immunology Laboratory, Hopital Neurologique, Lyon, France
    Intensive Care Med 32:1175-83. 2006
    ..We assessed whether a low monocyte human leukocyte antigen-DR (mHLA-DR) expression, proposed as a marker of immunosuppression, is an independent predictor of mortality in patients who survived the initial 48 h of septic shock...
  23. doi request reprint l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial
    Carine Domenech
    Institut d Hemato Oncologie pédiatrique, Hospices Civils de Lyon, Universite Claude Bernard, France
    Br J Haematol 153:58-65. 2011
    ..Other expected adverse events were comparable to those observed with E. colil-ASNase and there was also no difference between the three doses of GRASPA(®) ...
  24. pmc Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
    Sylvie Erpeldinger
    University college of General Medicine, University Claude Bernard Lyon 1, Lyon, France
    BMC Endocr Disord 16:39. 2016
    ..However, the benefit/risk balance of insulin remains controversial. Our aim was to determine the efficacy and safety of insulin vs. hypoglycaemic drugs or diet/placebo on clinically relevant endpoints...
  25. pmc Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population
    Riad Kahoul
    Novadiscovery SAS, 60 avenue Rockefeller, 69008 Lyon, France UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, CNRS, UCB Lyon 1 Bât Grégor Mendel, 43 Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France
    J R Soc Interface 11:20140867. 2014
    ..Hence the OMES approach is a practical, useful alternative which will help to overcome the limitations of treatment decision-making based uniquely on CPGs. ..
  26. pmc Is there excess mortality in women screened with mammography: a meta-analysis of non-breast cancer mortality
    Sylvie Erpeldinger
    Department of General Medicine, Universite Claude Bernard Lyon1, 69000, Lyon, France
    Trials 14:368. 2013
    ..The objective of our meta-analysis and systematic review was to analyze non-breast cancer mortality in women screened with mammography versus non-screened women to determine whether there is excess mortality caused by screening...
  27. ncbi request reprint Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data
    Behrouz Kassai
    INSERM, CIC201, EPICIM, Lyon, France
    Epilepsia 49:343-8. 2008
    ..The two RCTs identified, however, were performed with the same objectives and design and showed that seizure frequency is greatly reduced by stiripentol in children with SMEI after 2 months of treatment...
  28. doi request reprint Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis:GLUCOSE DINET protocol - Rational and design
    Guillaume Grenet
    Hospices Civils de Lyon, Service de Pharmacologie Clinique et Essais Thérapeutiques, Bp8071, 69376, Lyon, France
    Fundam Clin Pharmacol . 2016
    ..A ranking of the drugs will be proposed. Our network meta-analysis should allow a clinically relevant ranking of the contemporary antidiabetic drugs. This article is protected by copyright. All rights reserved...
  29. pmc Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Hai Ha Le
    Laboratoire de Biologie et Biométrie Evolutive Equipe Modélisation des Effets Thérapeutiques, UMR 5558 Université Claude Bernard Lyon1, Lyon, France
    PLoS ONE 11:e0145958. 2016
    ..Our study aimed to assess the efficacy of AAs on mortality including SCD, hospitalization admission and several common adverse effects...
  30. pmc Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis
    Catherine Cornu
    INSERM, CIC201, Lyon, France CHU Lyon, Service de Pharmacologie Clinique, Lyon, France Université de Lyon, UMR 5558, Lyon, France Hospices civils de Lyon, Hopital Louis Pradel, Bron Cedex, France
    Br J Clin Pharmacol 78:24-32. 2014
    ..Our aim was to identify, appraise, select and analyse all high-quality research evidence relevant to the question of the clinical impact of CNI-sparing strategies in heart transplant patients...
  31. pmc Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach
    Michel Tod
    Hospices Civils de Lyon, Universite de Lyon, Universite Lyon 1, 69000, Lyon, France
    AAPS J 15:1242-52. 2013
    ..The proposed approach will help (1) to identify comedications and population at risk, (2) to adapt dosing regimens, and (3) to prioritize the clinical pharmacokinetic studies to be done. ..
  32. ncbi request reprint J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data
    Florent Boutitie
    Claude Bernard University, Lyon, France
    Ann Intern Med 136:438-48. 2002
    ..However, several studies in hypertensive patients receiving treatment have described this relationship as J-shaped, with an increased risk for events in patients with low blood pressure...
  33. ncbi request reprint [The difficulty of measurement of placebo effect]
    Rémy Boussageon
    Département de médecine générale, Universite Claude Bernard, Lyon, France
    Therapie 61:185-90. 2006
    ..And secondly, the question is also raised of the interest for medical care of objectifying those effects...
  34. doi request reprint [Public clinical trials: which kind of monitoring should be used?]
    Catherine Cornu
    Service de Pharmacologie Clinique, Lyon, France
    Therapie 68:135-41. 2013
    ..Our objective was to describe the most frequent quality failures, how they impact trial results, and identify the most efficient monitoring strategies using published articles and reports...
  35. doi request reprint Expected impact of a public health intervention in the presence of synergistic risk factors
    Hadrien Charvat
    Universite Claude Bernard Lyon 1, 43 Boulevard du 11 Novembre 1918, F 69100, Villeurbanne, France
    J Clin Epidemiol 66:445-52. 2013
    ....
  36. doi request reprint Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial
    Caroline Scholtes
    Hospices Civils de Lyon, Hopital de la Croix Rousse, Laboratory of Virology, Lyon, France
    Therapie 67:423-7. 2012
    ..To test the modulation of farnesoid X receptor activity on the replication of hepatitis C virus in chronically infected patients...
  37. doi request reprint Efficiency of physical rehabilitation on postural imbalance after stroke: Systematic review and meta-analysis
    Aurélien Hugues
    Service de médecine physique et réadaptation, Hopital Henry Gabrielle, Hospices Civils de Lyon, plate forme mouvement et handicap, Saint Genis Laval, Lyon, France Inserm UMR S 1028, CNRS UMR 5292, IMPACT, Centre de Recherche en Neurosciences de Lyon, Universite Lyon 1, Lyon, France Electronic address
    Ann Phys Rehabil Med 59:e78. 2016
    ..Balance disorders are frequently seen after stroke resulting in limited physical activities. The effects of current physical rehabilitations aiming at reducing postural imbalance are varied with low levels of evidence...
  38. doi request reprint Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals
    Garry Taverny
    UMR5558 Service de Pharmacologie Clinique et Essais Thérapeutiques, Universite Claude Bernard Lyon 1, Lyon, France
    Cochrane Database Syst Rev 3:CD011745. 2016
    ....
  39. doi request reprint Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis
    Claudio Monteiro Sousa
    Novadiscovery, 60, avenue Rockefeller, 69008 Lyon, France Université Claude Bernard Lyon 1, CNRS, UMR 5558, Laboratoire de Biometrie et Biologie Evolutive, équipe Évaluation et modélisation des effets thérapeutiques, 7, Rue Guillaume Paradin, 69007 Lyon, France Electronic address
    C R Biol 338:635-42. 2015
    ..The use of functional analysis helped us identify discriminating biological mechanisms, such as the mTOR signaling pathway, between the pathological cases of sepsis and non-pathological (i.e., the artificially induced SIRS) cases. ..
  40. ncbi request reprint [Information and active patient participation using an interactive booklet in the prescription of antihypertensive drugs in primary care]
    Maud Keriel-Gascou
    Université Lyon 1 Département de medecine générale, Lyon, France
    Sante Publique 25:193-201. 2013
    ..The purpose of this study was to develop an interactive booklet designed to inform and involve patients with a view to preventing adverse drug events...
  41. doi request reprint Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure
    Anne Charlotte Castellan
    Universite de Lyon, F 69000, Lyon, Universite Lyon 1, CNRS UMR5558, Laboratoire de Biometrie et Biologie Evolutive, Equipe Modélisation et Evaluation des Thérapeutiques, 7 rue Guillaume Paradin, 69007 Lyon, France
    Clin Pharmacokinet 52:199-209. 2013
    ..We then developed dosing recommendations based on genotypes and compared them to current Epar/Vidal dosing guidelines...